EUCTR2016-000118-31-GB
进行中（未招募）
1 期
A randomised phase II double-blinded placebo-controlled trial of intravenous immunoglobulins and rituximab in patients with antibody-associated psychosis (SINAPPS2) - IVIG and rituximab in antibody-associated psychosis - SINAPPS2
Cambridge University Hospitals NHS Foundation Trust and the University of Cambridge0 个研究点目标入组 80 人2016年11月22日
适应症Antibody associated PsychosisTherapeutic area: Psychiatry and Psychology [F] - Mental Disorders [F03]
相关药物IVIG
概览
- 阶段
- 1 期
- 干预措施
- 未指定
- 疾病 / 适应症
- Antibody associated Psychosis
- 发起方
- Cambridge University Hospitals NHS Foundation Trust and the University of Cambridge
- 入组人数
- 80
- 状态
- 进行中（未招募）
- 最后更新
- 7年前
概览
简要总结
暂无简介。
研究者
入排标准
入选标准
- •To be included in the trial the patient must have:
- •Patient or legal representative is willing and able to provide informed consent.
- •Acute psychosis for at least 2 weeks (defined as symptomatic on the PANSS scale by score equal to or greater than 4 on P1, G9, P3, P2, G5, N1, N4, N6\).
- •This may either be a first episode or relapse after remission (remission defined as PANSS\=3 on PANSS items P1, G9, P3, P2, G5, N1, N4, N6 for previous 6 months).
- •Serum or CSF neuronal membrane autoantibodies at pathological levels (including NMDAR, LGI1 and other)
- •Are the trial subjects under 18? no
- •Number of subjects for this age range: 0
- •F.1\.2 Adults (18\-64 years) yes
- •F.1\.2\.1 Number of subjects for this age range 78
- •F.1\.3 Elderly (\>\=65 years) yes
排除标准
- •The presence of any of the following will preclude patient inclusion:
- •Duration of current episode of psychosis greater than 24 months.
- •Alternative co\-existing severe neurological disease, including tumour, hippocampal sclerosis with refractory epilepsy, probable dementia with evidence of atrophy on brain imaging, moderate or severe learning disability.
- •Any evidence of a current acute encephalopathy (for instance coma, seizures).
- •Hepatitis B, Hepatitis C or HIV positivity; severe hypogammaglobulinaemia.
- •Previous malignancy (to be usually excluded unless agreed with CI).
- •Pregnant, breast feeding or inadequate contraception if female.
- •Hypersensitivity or absolute contra\-indication to any study medication, murine proteins or excipients.
- •Live vaccine within last 3 months.
- •Previous treatment with rituximab in the past 12 months.
结局指标
主要结局
未指定
相似试验
已完成
不适用
The effect of vitamin supplementation, genotype and homocysteine on migraine frequency and severity in females diagnosed with migraine with aura.Migraine with auraAlternative and Complementary Medicine - Other alternative and complementary medicineNeurological - Other neurological disordersACTRN12609000275268Griffith University250
进行中（未招募）
不适用
Comparison of three doses of tiotropium inhalation solution delivered via a device called Respimat® inhaler with the aim to evaluate the efficacy and the safety of tiotropium. Patients with moderate persistent asthma will receive each treatment for 4 weeks once daily: 1.25, 2.5, 5.0 microgram tiotropium and placebo. The sequence of the 4 treatments will be randomly assigned to the patients, and neither the patient nor the treating investigator knows when the patient gets which treatment.moderate persistent asthmaMedDRA version: 14.0Level: LLTClassification code 10003555Term: Asthma bronchialSystem Organ Class: 10038738 - Respiratory, thoracic and mediastinal disordersTherapeutic area: Diseases [C] - Respiratory Tract Diseases [C08]EUCTR2010-018471-26-DEBoehringer Ingelheim Pharma GmbH & Co. KG120
进行中（未招募）
不适用
A Phase II randomised, double-blind, placebo controlled, cross-over efficacy and safety comparison of three doses of tiotropium inhalation solution delivered via Respimat® inhaler (1.25, 2.5 and 5.0 µg once daily) versus placebo in patients with moderate persistent asthma. - TinA dose confirmation in GINA 3/4moderate persistent asthmaMedDRA version: 13.1Level: LLTClassification code 10003555Term: Asthma bronchialSystem Organ Class: 10038738 - Respiratory, thoracic and mediastinal disordersEUCTR2010-018471-26-ATBoehringer Ingelheim RCV GmbH & Co KG120
进行中（未招募）
不适用
europrotection with phenytoin in optic neuritisAcute demyelinating optic neuritisMedDRA version: 16.0Level: PTClassification code 10030942Term: Optic neuritisSystem Organ Class: 10029205 - Nervous system disordersTherapeutic area: Diseases [C] - Nervous System Diseases [C10]EUCTR2011-003475-11-GBniversity College London (UCL)
进行中（未招募）
1 期
Phase II study with placebo to evaluate the efficacy and safety of bacterial collagenase administered in patients with Dupuytren's contractureDupuytren contractureMedDRA version: 20.0Level: PTClassification code 10013872Term: Dupuytren's contractureSystem Organ Class: 10028395 - Musculoskeletal and connective tissue disordersTherapeutic area: Diseases [C] - Skin and Connective Tissue Diseases [C17]EUCTR2022-000666-17-ATFidia Farmaceutici Spa72